Annual Meeting • November 10-12


Program Purpose

The Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting includeed updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.

Following SITC’s tradition of collaborating to advance the field, the 32nd Annual Meeting featured numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. The meeting concluded with the Hot Topic Symposium, an in-depth look at an emerging topic in the field. 

32nd Annual Meeting Organizers

Charles G. Drake, MD, PhDColumbia University Medical Center
Susan M. Kaech, PhDYale University
Marcela V. Maus, MD, PhDMassachusetts General Hospital Cancer Center
Laura S. Wood, RN, MSN, OCNCleveland Clinic Taussig Cancer Institute

Intended Audience

The audience included U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

Americans with Disabilities Act

handicap.pngEvent staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the live event at +1 414-271-2456.

Annual Program Oversight Committee

Chair: Mario Sznol, MDYale School of Medicine
Charlie Garnett Benson, PhDGeorgia State University
Elizabeth A. Repasky, PhDRoswell Park Cancer Institute

Educational Objectives

Upon completion of this meeting, participants will be able to:

  • Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
  • Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
  • Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention

For information on continuing medical education credits available through the 32nd Annual Meeting, please visit our Continuing Education webpage.


The SITC Annual Meeting is supported in part by grants from 7 Hills Pharma, LLC, AbbVie, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bayer Healthcare Pharmaceuticals U.S., Bristol-Myers Squibb, Celgene Corporation, Celldex Therapeutics, Inc., Dendreon Pharmaceuticals North America LLC, Fluidigm, Genentech, HalioDx, Idera Pharmaceuticals, Incyte Corporation, Janssen Research & Development, LLC, Kite Pharma, Inc., Merck & Co., Inc., NanoString Technologies, Novartis, Novartis Pharmaceuticals Corporation, The Parker Institute for Cancer Immunotherapy, Pfizer, Inc., and Prometheus Laboratories Inc., and Regeneron Pharmaceuticals, Inc.